120
Participants
Start Date
March 1, 2018
Primary Completion Date
January 26, 2021
Study Completion Date
July 14, 2021
fitusiran
by SC injection
factor concentrates
by intravenous (IV) injection
Investigational Site Number 8804, Taipei
Investigational Site Number 8801, Taipei
Investigational Site Number 3602, Budapest
Investigational Site Number 6101, Camperdown
Investigational Site Number 4501, Copenhagen
Investigational Site Number 2701, Parktown
Investigational Site Number 6104, Prahran
Investigational Site Number 8204, Seoul
Investigational Site Number 4906, Leipzig
Investigational Site Number 2702, Port Elizabeth
Investigational Site Number 6103, Murdoch
Investigational Site Number 4904, Berlin
Investigational Site Number 9008, Gaziantep
Investigational Site Number 3402, Madrid
Investigational Site Number 128, Gainesville
Investigational Site Number 8808, Taoyuan District
Investigational Site Number 103, Tampa
Investigational Site Number 9005, Istanbul
Investigational Site Number 3904, Padua
Investigational Site Number 8202, Daejeon
Investigational Site Number 9009, Kayseri
Investigational Site Number 8807, Taichung
Investigational Site Number 8805, Taichung
Investigational Site Number 110, Akron
Investigational Site Number 125, Ann Arbor
Investigational Site Number 9701, Ramat Gan
Investigational Site Number 8005, Mykolaiv
Investigational Site Number 9006, Samsun
Investigational Site Number 4905, Frankfurt am Main
Investigational Site Number 6004, Ampang
Investigational Site Number 3303, Lyon
Investigational Site Number 119, New Orleans
Investigational Site Number 0140, Little Rock
Investigational Site Number 3305, Paris
Investigational Site Number 3301, Rouen
Investigational Site Number 8002, Lviv
Investigational Site Number 6002, Johor Bahru
Investigational Site Number 6003, Kota Kinabalu
Investigational Site Number 111, Las Vegas
Investigational Site Number 8605, Hangzhou
Investigational Site Number 8604, Beijing
Investigational Site Number 8603, Shanghai
Investigational Site Number 9106, Lucknow
Investigational Site Number 8601, Tianjin
Investigational Site Number 9104, Jaipur
Investigational Site Number 9109, Mumbai
Investigational Site Number 9108, Mumbai
Investigational Site Number 9103, Pune
Investigational Site Number 8602, Guangzhou
Investigational Site Number 9102, Bangalore
Investigational Site Number 9105, Vellore
Investigational Site Number 102, Chicago
Investigational Site Number 9111, Mumbai
Investigational Site Number 8105, Isehara
Investigational Site Number 8104, Saitama
Investigational Site Number 8201, Busan
Investigational Site Number 9002, Adana
Investigational Site Number 9004, Antalya
Investigational Site Number 9003, Izmir
Investigational Site Number 8001, Kyiv
Investigational Site Number 8003, Kyiv
Investigational Site Number 4402, Glasgow
Investigational Site Number 4407, London
Investigational Site Number 4401, London
Genzyme, a Sanofi Company
INDUSTRY